Bringing together world leaders in integrating treatment-use trials into the clinical development of new therapeutics for serious diseases.
National Press Club
Get on the alert list for the “Industry Best Practices” publication and for Expanded Access 3.0 program updates!
2017 FDARA (PDUFA VI) calls for better patient representation in the clinical development process through a combination research trials and expanded access trials. Join the discussion on optimizing these two channels for engaging more patients.
The Summit is for unbiased, intellectual discussion on how early access works and how it can be put to better use. Our all-star panelists will cut through the recent noise that has obscured the core issues of feasibility, ethics, and value.
A Few of our featured speakers
Frank Young, MD, PhD
Executive Vice President Clinical & Reg Affairs, TissueTech Inc.; Former FDA Commissioner, 1984-1989
The National Press Club
The 2020 Expanded Access Summit will take place in the Ballroom of the National Press Club, a historic venue at the heart of Washington D.C.
OFFICIAL CONFERENCE HOTEL
Located just around the corner from our conference venue at the National Press Club, the JW Mariott is within easy walking distance of the White House, the National Mall, Ford’s Theatre and the Smithsonian Museums.
National Press Club
Join Attendees from world-class
companies and organizations
2017 companies included Pfizer, Takeda, Janssen, Bayer, Eli Lilly, Biogen, Alnylam, Vertex, Bluebird, Amicus, Ultragenyx, AmpliPhi, Wave Life Sciences, Neuralstem, Incyte, Asuragen, Astellas, Tesaro, Ovid, Spectrum, ALS Association, Parent Project Muscular Dystrophy, Kids V Cancer, BIO, FDA, NIH, Patient Advocate Foundation, the FNIH Biomakers Consortium, and more.
Past Attendees by Organization Type
- Life Science Companies 60% 60%
- Government & Non-Profits 22% 22%
- Service Providers 18% 18%
Industry Attendees by Job Function
- Clinical Development and Research 35% 35%
- Medical Affairs 31% 31%
- Central/Executive 18% 18%
- Regulatory Affairs 16% 16%